|
Takeda Pharmaceutical Company Limited (TAK) DCF Valuation
JP | Healthcare | Drug Manufacturers - Specialty & Generic | NYSE
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Takeda Pharmaceutical Company Limited (TAK) Bundle
Gain insight into your Takeda Pharmaceutical Company Limited (TAK) valuation analysis using our sophisticated DCF Calculator! This Excel template comes preloaded with actual (TAK) data, enabling you to adjust forecasts and assumptions to accurately determine the intrinsic value of Takeda Pharmaceutical Company Limited.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21,855.1 | 21,235.1 | 23,700.0 | 26,744.5 | 28,313.5 | 30,258.9 | 32,337.9 | 34,559.8 | 36,934.4 | 39,472.1 |
| Revenue Growth, % | 0 | -2.84 | 11.61 | 12.85 | 5.87 | 6.87 | 6.87 | 6.87 | 6.87 | 6.87 |
| EBITDA | 5,845.8 | 6,532.4 | 7,857.1 | 7,865.8 | 5,807.8 | 8,508.0 | 9,092.5 | 9,717.3 | 10,384.9 | 11,098.4 |
| EBITDA, % | 26.75 | 30.76 | 33.15 | 29.41 | 20.51 | 28.12 | 28.12 | 28.12 | 28.12 | 28.12 |
| Depreciation | 3,875.7 | 3,716.5 | 3,872.4 | 4,412.0 | 4,834.3 | 5,152.8 | 5,506.9 | 5,885.2 | 6,289.6 | 6,721.7 |
| Depreciation, % | 17.73 | 17.5 | 16.34 | 16.5 | 17.07 | 17.03 | 17.03 | 17.03 | 17.03 | 17.03 |
| EBIT | 1,970.1 | 2,815.9 | 3,984.7 | 3,453.8 | 973.5 | 3,355.1 | 3,585.7 | 3,832.0 | 4,095.3 | 4,376.7 |
| EBIT, % | 9.01 | 13.26 | 16.81 | 12.91 | 3.44 | 11.09 | 11.09 | 11.09 | 11.09 | 11.09 |
| Total Cash | 4,339.1 | 6,659.2 | 5,810.4 | 3,676.9 | 3,040.0 | 6,064.8 | 6,481.5 | 6,926.9 | 7,402.8 | 7,911.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 5,212.3 | 5,396.8 | 4,810.2 | 4,526.8 | 4,632.5 | 6,224.1 | 6,651.8 | 7,108.8 | 7,597.2 | 8,119.2 |
| Account Receivables, % | 23.85 | 25.41 | 20.3 | 16.93 | 16.36 | 20.57 | 20.57 | 20.57 | 20.57 | 20.57 |
| Inventories | 5,044.1 | 5,006.1 | 5,665.5 | 6,550.6 | 8,034.1 | 7,469.6 | 7,982.8 | 8,531.3 | 9,117.5 | 9,743.9 |
| Inventories, % | 23.08 | 23.57 | 23.9 | 24.49 | 28.38 | 24.69 | 24.69 | 24.69 | 24.69 | 24.69 |
| Accounts Payable | 1,405.3 | 1,541.3 | 1,965.2 | 2,041.6 | 2,124.7 | 2,246.3 | 2,400.6 | 2,565.6 | 2,741.9 | 2,930.3 |
| Accounts Payable, % | 6.43 | 7.26 | 8.29 | 7.63 | 7.5 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 |
| Capital Expenditure | -1,445.7 | -1,570.3 | -1,235.4 | -4,208.0 | -3,192.3 | -2,797.8 | -2,990.0 | -3,195.5 | -3,415.0 | -3,649.7 |
| Capital Expenditure, % | -6.61 | -7.39 | -5.21 | -15.73 | -11.27 | -9.25 | -9.25 | -9.25 | -9.25 | -9.25 |
| Tax Rate, % | -172.9 | -172.9 | -172.9 | -172.9 | -172.9 | -172.9 | -172.9 | -172.9 | -172.9 | -172.9 |
| EBITAT | -1,434.6 | 2,891.0 | 3,029.8 | 2,919.1 | 2,656.7 | 2,419.4 | 2,585.6 | 2,763.3 | 2,953.2 | 3,156.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -7,855.7 | 5,026.6 | 6,018.0 | 2,597.8 | 2,792.4 | 3,869.0 | 4,315.9 | 4,612.5 | 4,929.4 | 5,268.1 |
| WACC, % | 2.56 | 4.92 | 4.36 | 4.56 | 4.92 | 4.26 | 4.26 | 4.26 | 4.26 | 4.26 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 20,196.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 5,373 | |||||||||
| Terminal Value | 237,329 | |||||||||
| Present Terminal Value | 192,609 | |||||||||
| Enterprise Value | 212,806 | |||||||||
| Net Debt | 29,125 | |||||||||
| Equity Value | 183,681 | |||||||||
| Diluted Shares Outstanding, MM | 1,580 | |||||||||
| Equity Value Per Share | 116.23 |
What You Will Receive
- Customizable Excel Template: A fully editable Excel-based DCF Calculator featuring pre-filled financial data for Takeda Pharmaceutical Company Limited (TAK).
- Real-World Insights: Access to historical data and forward-looking projections (highlighted in the yellow cells).
- Flexible Forecasting: Adjust key assumptions such as revenue growth, EBITDA margin, and WACC.
- Instant Calculations: Quickly observe how your inputs affect Takeda's valuation.
- Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
- Intuitive Layout: Organized for clarity and ease of navigation, complete with step-by-step guidance.
Key Features
- Customizable Forecast Inputs: Adjust essential metrics such as revenue growth, operating margin, and research & development expenses.
- Instant DCF Valuation: Automatically computes intrinsic value, NPV, and additional metrics in real-time.
- High-Precision Accuracy: Leverages Takeda’s actual financial data for reliable valuation results.
- Effortless Scenario Analysis: Evaluate various assumptions and analyze results with ease.
- Efficiency Booster: Remove the hassle of constructing intricate valuation models from the ground up.
How It Works
- Download the Template: Gain immediate access to the Excel-based TAK DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model will automatically compute Takeda’s intrinsic value.
- Test Scenarios: Experiment with different assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the findings to inform your investment or financial analysis.
Why Choose This Calculator for Takeda Pharmaceutical Company Limited (TAK)?
- All-in-One Solution: Features DCF, WACC, and financial ratio analyses tailored for Takeda.
- Flexible Inputs: Modify the yellow-highlighted fields to explore different financial scenarios.
- In-Depth Analysis: Automatically computes Takeda’s intrinsic value and Net Present Value.
- Preloaded Information: Access to historical and projected data for accurate evaluations.
- High-Quality Standards: Perfect for financial analysts, investors, and business consultants focusing on pharmaceuticals.
Who Should Use This Product?
- Individual Investors: Gain insights to make informed decisions about buying or selling Takeda Pharmaceutical Company Limited (TAK) stock.
- Financial Analysts: Enhance valuation processes with accessible financial models tailored for Takeda (TAK).
- Consultants: Provide clients with accurate and timely valuation insights on Takeda Pharmaceutical Company Limited (TAK).
- Business Owners: Learn how large pharmaceutical companies like Takeda (TAK) are valued to inform your own business strategy.
- Finance Students: Master valuation techniques using real-world data and case studies focused on Takeda (TAK).
What the Template Contains
- Pre-Filled DCF Model: Takeda Pharmaceutical Company Limited’s financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Takeda’s profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.